BIOR Biora Therapeutics
- 0.5872
- -0.0626-9.63%
- 0.6200
- +0.0328+5.59%
Biora Therapeutics News
Biora Therapeutics Achieves ISO 13485 Certification, Demonstrating The Co's Commitment To Compliance With The Most Rigorous Global Regulatory And Quality Standards
Express News | Biora Therapeutics Inc - No Payments Will Be Made by Either Party
Express News | Biora Therapeutics - in Sept 2024, Following Hearing on Biora's Summary Judgment Motion, Co and Ravgen Inc Entered Into Settlement Agreement
Biora Therapeutics Granted Extension to Regain Compliance With Nasdaq
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Express News | Biora Therapeutics Inc Files for Resale of up to 96.7 Mln Shares by the Selling Stockholders - SEC Filing
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (Vs US$1.47 Loss in 2Q 2023)
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Syros Pharmaceuticals SYRS Phase 2 Data; Biora Therapeutics BIOR Funding
Biora Therapeutics: Outperforming With Strong Q2 Financials and Clinical Advancements
Earnings Call Summary | Biora Therapeutics(BIOR.US) Q2 2024 Earnings Conference
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Biora Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results and a Year-over-year Increase in Q2 Sales Results.
Biora Therapeutics Restructures Debt and Issues New Securities
Biora Therapeutics | 10-Q: Q2 2024 Earnings Report
Biora Therapeutics GAAP EPS of -$0.04 Beats by $0.41, Revenue of $0.32M
Biora Therapeutics 2Q Loss/Shr 4c >BIOR
Earnings Flash (BIOR) BIORA THERAPEUTICS Posts Q2 Revenue $318,000
Analysis
Price Target
No Data
No Data